Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug research tax credits

Executive Summary

Rep. Stark's (D-Calif.) drug tax credit bill would deny drug manufacturers a research tax credit for drugs that are sold at a lower price in Organization for Economic Cooperation & Development countries than in the U.S. The bill would not affect foreign tax credits (1"The Pink Sheet" Jan. 3, p. 16). Stark expects to introduce the bill in February

You may also be interested in...



Stark Foreign Tax Credit Bill Would Open Fifth Front In Rx Pricing Debate

Rep. Stark (D-Calif.) will attempt to open a fifth front in the 2000 legislative debate over pharmaceutical pricing with a bill to deny foreign tax credits to companies that charge higher prices in the U.S. than in other industrialized countries.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

UsernamePublicRestriction

Register

LL1135975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel